Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 426

Sort by

Sort Order Select

Journal Articles

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

Amelia R. Wilhelm, B.S., Nicole A. Parsons, B.S., Charles T. Esmon, PhD, Rodney M. Camire, PhD, Lindsey A. George, MD

Blood (2019) 134 (Supplement_1): 93.

https://doi.org/10.1182/blood-2019-124493

Published: 2019

Journal Articles

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Ashley Pinchinat, MD, Neida Otero, Harshini Mahanti, BS, MSCR, Erin Morris, RN, BSN, Adele Brudnicki, MD, Deborah Friedman, MD, Simon Li, MD, Oya Levendoglu-Tugal, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 2443.

https://doi.org/10.1182/blood-2019-130468

Published: 2019

Journal Articles

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Debra Hoppensteadt, PhD, Emily Bontekoe, Fakiha Siddiqui, Ambar Farooqui, Omer Iqbal, MD, Walter Jeske, PhD, Jeanine Walenga, PhD, Alfonso J Tafur, MD MS, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 3374.

https://doi.org/10.1182/blood-2019-131221

Published: 2019

Journal Articles

Adeno-Associated Virus Mediated Delivery of a TFPI Antibody Restores Hemostasis in Mouse Model of Hemophilia

Swapnil Rakhe, MS, Reema Jasuja, PhD, Rajani Shelke, Anagha Sawant, Suryanarayan Somanathan, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2019) 134 (Supplement_1): 3357.

https://doi.org/10.1182/blood-2019-130054

Published: 2019

Journal Articles

The Real World Experience Regarding the Safety of Rivaroxaban and Apixaban in Venous Thromboembolism Patients with High Bleeding Risk

Haoxu Ouyang, MD PhD, Ratesh Khillan, Nyein Htway Yu, MBBS, MD, Mohan Preet, MD

Blood (2019) 134 (Supplement_1): 4927.

https://doi.org/10.1182/blood-2019-132283

Published: 2019

Journal Articles

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Gita Massey, Michael F. Guerrera, MD, Lance Ballester, MS, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 1137.

https://doi.org/10.1182/blood-2019-122569

Published: 2019

Journal Articles

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Siddharth Mehrotra, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Omer Iqbal, MD, Alfonso J Tafur, MD MS, Bruce Lewis, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1155.

https://doi.org/10.1182/blood-2019-131907

Published: 2019

Journal Articles

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Fakiha Siddiqui, Alfonso J Tafur, MD MS, Debra Hoppensteadt, PhD, Jeanine Walenga, PhD, Walter Jeske, PhD, Emily Bontekoe, Ahmed Kouta, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1158.

https://doi.org/10.1182/blood-2019-127072

Published: 2019

Journal Articles

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Anuja Khan, PhD, Krisjela Shishko, BS, Sam Arcidiacono, BS, Khanh Bui, BS, Genmin Lu, Pamela B. Conley, PhD, Anne Winkler, MD

Blood (2019) 134 (Supplement_1): 1153.

https://doi.org/10.1182/blood-2019-126254

Published: 2019

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Effect of Sulfated NON-Anticoagulant Low Molecular Weight Heparin in Cancer and NON-Cancer Associated Thrombosis

Kavitha Godugu, PhD, Shymaa Mousa, Noureldien Hassan Elsayed Darwish, MDPhDBS, Shaker A Mousa, PhD BPharm, MBA, MSc

Blood (2019) 134 (Supplement_1): 3670.

https://doi.org/10.1182/blood-2019-130992

Published: 2019

Journal Articles

Molecular Interaction Site on Procoagulant Skeletal Muscle Myosin for Factor Xa-Dependent Prothrombin Activation

Hiroshi Deguchi, MD PhD, Zihan Guo, Mohammed Hayat, Elsa Pflimlin, Weijun Shen, John H. Griffin, PhD

Blood (2019) 134 (Supplement_1): 3622.

https://doi.org/10.1182/blood-2019-129161

Published: 2019

Journal Articles

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

Ammon Fager, MD PhD, Maureane Hoffman, MD PhD, Dougald Monroe, PhD

Blood (2019) 134 (Supplement_1): 3623.

https://doi.org/10.1182/blood-2019-124428

Published: 2019

Journal Articles

Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo

Jevgenia Zilberman-Rudenko, Hiroshi Deguchi, MD PhD, Mohammed Hayat, Meenal Shukla, PhD, Jennifer Nagrampa Orje, Zihan Guo, Tine Wyseure, PhD, Laurent O Mosnier, Owen J T McCarty, PhD, Zaverio M. Ruggeri, MD, John H. Griffin, PhD

Blood (2019) 134 (Supplement_1): 3632.

https://doi.org/10.1182/blood-2019-129312

Published: 2019

Journal Articles

In Vitro and In Vivo Characterization of Marstacimab, an Anti-TFPI Antibody

Chuenlei Parng, PhD, Macy Jin, PhD, Matthew Holsti, PhD, Susan Benard, Swapnil Rakhe, MS, Sunita R. Patel-Hett, PhD, Alison Joyce, Rob Webster, Debra D Pittman, MS

Blood (2019) 134 (Supplement_1): 2391.

https://doi.org/10.1182/blood-2019-130327

Published: 2019

Journal Articles

Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents

Bruce A. Sullenger, PhD

Blood (2019) 134 (Supplement_1): SCI-16.

https://doi.org/10.1182/blood-2019-121056

Published: 2019

Journal Articles

NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition

Viviane S. De Paula, Nikolaos G. Sgourakis, Ivo M. B. Francischetti, Fabio C. L. Almeida, Robson Q. Monteiro, Ana Paula Valente

Blood (2019) 134 (8): 699–708.

https://doi.org/10.1182/blood.2018889493

Published: 2019

Includes: Supplemental data

Journal Articles

Reversing anti–factor Xa agents and the unmet needs in trauma patients

Beverley J. Hunt, Matthew D. Neal, Jakob Stensballe

Blood (2018) 132 (23): 2441–2445.

https://doi.org/10.1182/blood-2018-06-850396

Published: 2018

Journal Articles

Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms

Christina Berens, Heiko Rühl, MD, Jens Müller, Johannes Oldenburg, MD PhD, Peter Brossart, MD, Dominik Wolf, MD, Bernd Pötzsch

Blood (2018) 132 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2018-99-118487

Published: 2018

Journal Articles

Comparison of Second and First Generation of Andexanet Alfa in a Porcine Polytrauma Model with Apixaban Anticoagulation

Oliver Grottke, MD PhD MPH, Necib Akman, MD, Till Braunschweig, MD, Pamela B. Conley, PhD, Rolf Rossaint, MD

Blood (2018) 132 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2018-99-114542

Published: 2018

NARROW

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Adeno-Associated Virus Mediated Delivery of a TFPI Antibody Restores Hemostasis in Mouse Model of Hemophilia

The Real World Experience Regarding the Safety of Rivaroxaban and Apixaban in Venous Thromboembolism Patients with High Bleeding Risk

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Effect of Sulfated NON-Anticoagulant Low Molecular Weight Heparin in Cancer and NON-Cancer Associated Thrombosis

Molecular Interaction Site on Procoagulant Skeletal Muscle Myosin for Factor Xa-Dependent Prothrombin Activation

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo

In Vitro and In Vivo Characterization of Marstacimab, an Anti-TFPI Antibody

Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents

NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition

Reversing anti–factor Xa agents and the unmet needs in trauma patients

Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms

Comparison of Second and First Generation of Andexanet Alfa in a Porcine Polytrauma Model with Apixaban Anticoagulation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only